{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:26:38Z","timestamp":1785389198899,"version":"3.55.0"},"reference-count":0,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical and Investigative Medicine"],"published-print":{"date-parts":[[2021,6,14]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Infliximab (INX) has been approved for treating Crohn disease (CD) for many years, showing promis-ing efficacy in the clinic. However, the efficacy of the drug and the prognosis of CD vary significantly with dif-ferent locations of disease pathology. This study evaluated the efficacy of INX and prognosis in CD in different locations of disease pathology using systematic meta-analysis. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> We used \u201cInfliximab OR Remicade OR Avakine OR Inflectra OR Renflexis OR Remsima OR IgG1k monoclonal antibody\u201d AND \u201cCrohn\u2019s disease OR IBD OR inflammatory bowel disease\u201d as search strategies for searching in PubMed, Wanfang and Embase. A systematic meta-analysis for overall proportions was used to analyze the data. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Twelve studies involving 1,978 patients were included. The results confirmed that treatment with INX led to high clinical remission rates (82%, 95% CI: 64%-92%) and low relapse rates (4%, 95% CI: 2%-9%) in patients with CD. Our results also indicated that use of INX in patients with colon only (L2) CD led to lower clinical remission rates, and use of INX in patients with ileum and colon (L3) CD led to higher relapse rates. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Our findings show different remission rates depending on location of the disease and may be useful for clinicians\u2019 choice of therapeutics. <\/jats:p><\/jats:sec>","DOI":"10.25011\/cim.v44i2.36356","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T05:32:28Z","timestamp":1624339948000},"page":"E27-E35","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Efficacy of Infliximab in Patients With Crohn Disease in Different Locations of Disease Pathology: A Meta-Analysis"],"prefix":"10.3138","volume":"44","author":[{"given":"Chi-Zhou","family":"Jiang","sequence":"first","affiliation":[{"name":"School of Life Sciences, Nanjing University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Liang","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Biopharmacy, China Pharmaceutical University, Nanjing, China"},{"name":"Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories Inc., Changzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","container-title":["Clinical and Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cimonline.ca\/index.php\/cim\/article\/download\/36356\/27998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.25011\/cim.v44i2.36356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T18:11:37Z","timestamp":1741889497000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.25011\/cim.v44i2.36356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6,14]]}},"alternative-id":["10.25011\/cim.v44i2.36356"],"URL":"https:\/\/doi.org\/10.25011\/cim.v44i2.36356","relation":{},"ISSN":["1488-2353"],"issn-type":[{"value":"1488-2353","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]}}}